Effects on Bone Marrow and Spleen of FL Treatment Alone or in Combination With G-CSF
Site . | Control . | FL . | G-CSF . | FL + G-CSF . |
---|---|---|---|---|
Marrow | ||||
Cells/femur (× 106/femur) | 27.6 ± 1.1 | 22.0 ± 3.2* | 19.6 ± 0.9* | 18.6 ± 2.1* |
GM-CFC/femur | 18,000 ± 340 | 18,680 ± 413* | 3,200 ± 173* | 2,400 ± 120* |
BFU-E/femur | 796 ± 412 | 396 ± 280* | 0 | 0 |
CFU-mix/femur | 2,792 ± 1,312 | 2,264 ± 865 | 660 ± 245* | 0 |
CFU-S/femur | 5,405 ± 62 | 4,700 ± 34* | 825 ± 13* | 450 ± 112* |
Spleen | ||||
Cells/spleen (× 106/spleen) | 128 ± 23 | 115 ± 16 | 178 ± 21* | 232 ± 59* |
GM-CFC/spleen | 1,440 ± 321 | 1,880 ± 212* | 74,280 ± 816* | 257,580 ± 2,300* |
BFU-E/spleen | 0 | 664 ± 54 | 1,464 ± 112 | 16,200 ± 1,800 |
CFU-mix/spleen | 0 | 396 ± 68 | 12,796 ± 1,402 | 10,680 ± 888 |
CFU-S/spleen | 7,458 ± 86 | 3,583 ± 321* | 17,050 ± 554* | 22,500 ± 4,590* |
Site . | Control . | FL . | G-CSF . | FL + G-CSF . |
---|---|---|---|---|
Marrow | ||||
Cells/femur (× 106/femur) | 27.6 ± 1.1 | 22.0 ± 3.2* | 19.6 ± 0.9* | 18.6 ± 2.1* |
GM-CFC/femur | 18,000 ± 340 | 18,680 ± 413* | 3,200 ± 173* | 2,400 ± 120* |
BFU-E/femur | 796 ± 412 | 396 ± 280* | 0 | 0 |
CFU-mix/femur | 2,792 ± 1,312 | 2,264 ± 865 | 660 ± 245* | 0 |
CFU-S/femur | 5,405 ± 62 | 4,700 ± 34* | 825 ± 13* | 450 ± 112* |
Spleen | ||||
Cells/spleen (× 106/spleen) | 128 ± 23 | 115 ± 16 | 178 ± 21* | 232 ± 59* |
GM-CFC/spleen | 1,440 ± 321 | 1,880 ± 212* | 74,280 ± 816* | 257,580 ± 2,300* |
BFU-E/spleen | 0 | 664 ± 54 | 1,464 ± 112 | 16,200 ± 1,800 |
CFU-mix/spleen | 0 | 396 ± 68 | 12,796 ± 1,402 | 10,680 ± 888 |
CFU-S/spleen | 7,458 ± 86 | 3,583 ± 321* | 17,050 ± 554* | 22,500 ± 4,590* |
Data presented are the mean of 2 experiments ± 1 SD, each from 5 donors.
P < .005 v control.